Model-based patterns in prostate cancer mortality worldwide

British Journal of Cancer

Volumn 108, Issue 11, 2013, Pages 2354-2366

  Fontes, F ^a   Severo, M ^a,b   Castro, C ^a,c   Lourenco S ^a   Gomes, S ^a   Botelho, F ^a,d   La Vecchia, C ^e,f   Lunet, N ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c North Region Cancer Registry (RORENO)   (Portugal)

^d HOSPITAL DE BRAGA   (Portugal)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Cluster analysis; Mortality trends; Prostatic neoplasm

Indexed keywords

AGE; AGED; ARTICLE; CLUSTER ANALYSIS; HEALTH; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; STATISTICAL MODEL;

AGE FACTORS; AGED; CLUSTER ANALYSIS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MORTALITY; PROSTATIC NEOPLASMS; WORLD HEALTH;

EID: 84884183993     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.217     Document Type: Article

References (38)

1. Andriole GL, Crawford ED, Grubb RLr, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale P, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC (2012) Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2): 125–132.
2. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson J (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(48): 1708–1717.
3. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360(9327): 103–106.
4. Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F (2011) Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol 60(1): 1–15.
5. Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F, Miralbell R, Zanetti R (2008) Recent trends in prostate cancer mortality show a continuos decrease in several countries. Int J Cancer 123(2): 421–429.
6. Bray F, Lorlet-Tieulen J, Ferlay J, Forman D, Auvinen A (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46(17): 3040–3052.
7. Center MM, Jemal A, Lorlet-Tieulen J, Ward E, Ferlay J, Brawley O, Bray F (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61(6): 1079–1092.
8. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J (2008) Prostatecancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol 9(5): 445–452.
9. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (2007) Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160. IARC: Lyon.
10. Doll R, Smith P (1982) Comparison between registries: age-standardized rates. In: Cancer Incidence in Five Continents, Vol IV IARC Scientific Publication No 42, Waterhouse J, Muir C, Shanmugaratnam K, Powell J, Peacham D, Whelan S (eds), pp 671–675. International Agency for Research on Cancer: Lyon, France.
11. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schrõder FH, de Koning H (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 95(12): 868–878.
12. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101(6): 374–383.
13. Efron B, Tibshirani R (1997) Improvements on Cross-Validation: The 632þ Bootstrap Method. J Am Stat Assoc 92: 548–560.
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer: Lyon, France, Available from http://globocan.iarc.fr (accessed on 25 March 2012).
15. Feuer EJ, Merril RM, Hankey BF (1999) Cancer surveillance series: interpreting trends in prostate cancer—part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91(12): 1025–1032.
16. Fraley C, Raftery AE (2002) Model-based clustering, discriminant analysis, and density estimation. J Am Stat Assoc 97(458): 611–631.
17. Geran L, Tully P, Wood P, Thomas B (2005) Comparability of ICD-10 and ICD-9 for Mortality Statistics in Canada. Statistics Canada: Ottawa, Canada.
18. Hsing AW, Devesa SS (2001) Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23(1): 3–13.
19. International Agency for Research on Cancer (2010) Cancer Incidence in Five Continents, Volumes I to IX [database on the Internet]; Available from http://ci5.iarc.fr (accessed on 25 March 2011).
20. Klebba AJ (1980) Estimates of Selected Comparatibility Ratios based on Dual Coding of 1976 Death Certificates by the Eighth and Ninth Revisions of the International Classification of Diseases. Monthly Vital Statistics Report. National Center for Health Statistics: Hyattsville, Maryland, USA.
21. Kvaˆle R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass E, Bray F (2007) Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 99(24): 1881–1887.
22. Merril RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA (1999) Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 150(8): 848–860.
23. Mettlin C (2000) Impact of screening on prostate cancer rates and trends. Microsc Res Tech 51(4): 415–418.
24. Møller H (2001) Trends in incidence of testicular cancer and prostate cancer in Denmark. Hum Reprod 16(5): 1007–1011.
25. Muthén B (2006) Should substance use disorders be considered as categorical or dimensional? Addiction 101(Suppl 1): 6–16.
26. Norderhaug IN, Sandberg S, Fosså SD, Forland F, Malde K, Kvinnsland S, Traaholt I, Rossiné BK, Førde OH (2003) Health technology assessment and implications for clinical practice: the case of prostate cancer screening. Scand J Clin Lab Invest 63(5): 331–338.
27. Oliver SE, May MT, Gunnell D (2001) International trends in prostate-cancer mortality in the "PSA ERA". Int J Cancer 92: 893–898.
28. Peschel RE, Colberg JW (2003) Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4(4): 233–241.
29. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11): 981–990.
30. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D (1997) Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1(2): 1–96.
31. Soerjomataram I, Lorlet-Tieulen J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F (2012) Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet S0140-6736(12): 60919–60912.
32. The World Bank (2012) Analytical classifications for GNI. http://data.worldbank.org/about/country-classifications/a-short-history (accessed on 5 March 2013).
33. The World Bank (2012) World Development Indicators http://data.worldbank.org/indicator/NY.GNP.ATLS.CD/countries (accessed on 5 May 2013).
34. United Nations (2010) World Population Prospects: The 2010 Revision— Special Aggregates. Available from http://esa.un.org/unpd/wpp/index.htm (accessed on 30 May 2012).
35. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378(9809): 2104–2111.
36. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27(18): 2924–2930.
37. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei J, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole G, Culkin D, Wheeler T (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3): 203–213.
38. World Health Organization (2012) World Health Organization Statistical Information System. WHO Mortality Database; Available from http://www.who.int/whosis/mort/download/en/index.html (accessed on 30 May 2012).